Jerusalem: Saliva-based diagnostic technology available for licensing

Licensing opportunity

A diagnostic tool that has overcome a key barrier to detecting low-concentrations of biomarkers in human saliva has been developed by Aaron Palmon and Doron Aframian at the Hebrew University of Jerusalem–Hadassah School of Dental Medicine. The technology is now available for licensing through Yissum, the university’s technology transfer company.

Human saliva contains high amounts of alpha-amylase, a digestive protein which accounts for 60 per cent of saliva protein content, which can interfere with the quantification of biomarkers using conventional diagnostic tests. Palmon’s portable device uses modified potato starch to absorb the amylase, allowing accurate measurement of biomarkers present at low concentrations in human saliva samples.

The researchers say their noninvasive tool is cost-efficient and can be used to diagnose cancer, heart disease, diabetes, periodontal disease and HIV, diseases which are usually detected by blood or urine sample analysis.

Nava Swersky CEO of Yissum, said: “Professor Palmon’s technology paves the way for a quick and efficient, noninvasive diagnostic tool which may replace current invasive tests. The disposable device is an important addition to current diagnostic technologies and will contribute to patient welfare. We also believe it carries significant commercial potential.”